Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
3(25%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_3
6
50%
Ph phase_2
3
25%
Ph phase_4
2
17%

Phase Distribution

1

Early Stage

3

Mid Stage

8

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
6(50.0%)
Phase 4Post-market surveillance
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(9)
Terminated(3)

Detailed Status

Completed9
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 23 (25.0%)
Phase 36 (50.0%)
Phase 42 (16.7%)

Trials by Status

terminated325%
completed975%

Recent Activity

0 active trials
Showing 5 of 12
terminatedphase_4

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

NCT03968744
completedphase_4

Overnight Switch From Rasagiline To Safinamide

NCT03843944
completedphase_3

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

NCT03881371
terminatedphase_2

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

NCT01264861
terminatedphase_3

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

NCT00865579
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03968744Phase 4

Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease

Terminated
NCT03843944Phase 4

Overnight Switch From Rasagiline To Safinamide

Completed
NCT03881371Phase 3

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Completed
NCT01264861Phase 2

A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain Imaging

Terminated
NCT00865579Phase 3

Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients

Terminated
NCT01211587Phase 2

A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's Disease

Completed
NCT01113320Phase 2

Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects

Completed
NCT01027169Phase 1

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

Completed
NCT01286935Phase 3

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

Completed
NCT01187966Phase 3

Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease

Completed
NCT00642889Phase 3

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)

Completed
NCT00643045Phase 3

Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12